Details of the Drug

General Information of Drug (ID: DMESZQU)

Drug Name

Litenimod

Synonyms

Li-28; CpG oligonucleotide immunomodulator (cancer), Oligovax

Indication

Disease Entry	ICD 11	Status	REF
Glioblastoma multiforme	2A00.0	Phase 1	[1]
------------------------------------------------------------------------------------

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 5

Molecular Weight (mw)

8370

Logarithm of the Partition Coefficient (xlogp)

-4.3

Rotatable Bond Count (rotbonds)

152

Hydrogen Bond Donor Count (hbonddonor)

57

Hydrogen Bond Acceptor Count (hbondacc)

198

Chemical Identifiers

Formula: C256H322N95O129P25S25
IUPAC Name: 1-[5-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[5-(6-aminopurin-9-yl)-2-[[[5-(6-aminopurin-9-yl)-2-[[[5-(6-aminopurin-9-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
Canonical SMILES: CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)O
InChI: InChI=1S/C256H322N95O129P25S25/c1-101-44-330(248(371)317-227(101)354)166-18-110(353)137(431-166)54-405-481(380,506)468-123-31-179(339-88-292-192-205(261)274-79-283-214(192)339)444-150(123)67-418-483(382,508)457-112-20-167(326-14-10-162(257)305-244(326)367)432-138(112)55-407-487(386,512)461-116-24-172(332-46-103(3)229(356)319-250(332)373)440-146(116)63-415-499(398,524)477-132-40-188(348-97-301-201-223(348)309-240(270)313-236(201)363)452-158(132)75-426-484(383,509)460-115-23-170(329-17-13-165(260)308-247(329)370)435-141(115)58-410-496(395,521)471-127-35-183(343-92-296-196-209(265)278-83-287-218(196)343)451-157(127)74-425-505(404,530)480-135-43-191(351-100-304-204-226(351)312-243(273)316-239(204)366)455-161(135)78-429-493(392,518)467-122-30-178(338-52-109(9)235(362)325-256(338)379)439-145(122)62-414-498(397,523)473-129-37-185(345-94-298-198-211(267)280-85-289-220(198)345)446-152(129)69-420-491(390,516)465-120-28-176(336-50-107(7)233(360)323-254(336)377)437-143(120)60-412-489(388,514)463-118-26-174(334-48-105(5)231(358)321-252(334)375)442-148(118)65-417-500(399,525)478-133-41-189(349-98-302-202-224(349)310-241(271)314-237(202)364)453-159(133)76-427-485(384,510)458-113-21-168(327-15-11-163(258)306-245(327)368)433-139(113)56-408-494(393,519)469-125-33-181(341-90-294-194-207(263)276-81-285-216(194)341)448-154(125)71-423-503(402,528)475-130-38-186(346-95-299-199-212(268)281-86-290-221(199)346)447-153(130)70-421-492(391,517)466-121-29-177(337-51-108(8)234(361)324-255(337)378)438-144(121)61-413-497(396,522)472-128-36-184(344-93-297-197-210(266)279-84-288-219(197)344)445-151(128)68-419-490(389,515)464-119-27-175(335-49-106(6)232(359)322-253(335)376)436-142(119)59-411-488(387,513)462-117-25-173(333-47-104(4)230(357)320-251(333)374)441-147(117)64-416-501(400,526)479-134-42-190(350-99-303-203-225(350)311-242(272)315-238(203)365)454-160(134)77-428-486(385,511)459-114-22-169(328-16-12-164(259)307-246(328)369)434-140(114)57-409-495(394,520)470-126-34-182(342-91-295-195-208(264)277-82-286-217(195)342)449-155(126)72-424-504(403,529)476-131-39-187(347-96-300-200-213(269)282-87-291-222(200)347)450-156(131)73-422-502(401,527)474-124-32-180(340-89-293-193-206(262)275-80-284-215(193)340)443-149(124)66-406-482(381,507)456-111-19-171(430-136(111)53-352)331-45-102(2)228(355)318-249(331)372/h10-17,44-52,79-100,110-161,166-191,352-353H,18-43,53-78H2,1-9H3,(H,380,506)(H,381,507)(H,382,508)(H,383,509)(H,384,510)(H,385,511)(H,386,512)(H,387,513)(H,388,514)(H,389,515)(H,390,516)(H,391,517)(H,392,518)(H,393,519)(H,394,520)(H,395,521)(H,396,522)(H,397,523)(H,398,524)(H,399,525)(H,400,526)(H,401,527)(H,402,528)(H,403,529)(H,404,530)(H2,257,305,367)(H2,258,306,368)(H2,259,307,369)(H2,260,308,370)(H2,261,274,283)(H2,262,275,284)(H2,263,276,285)(H2,264,277,286)(H2,265,278,287)(H2,266,279,288)(H2,267,280,289)(H2,268,281,290)(H2,269,282,291)(H,317,354,371)(H,318,355,372)(H,319,356,373)(H,320,357,374)(H,321,358,375)(H,322,359,376)(H,323,360,377)(H,324,361,378)(H,325,362,379)(H3,270,309,313,363)(H3,271,310,314,364)(H3,272,311,315,365)(H3,273,312,316,366)
InChIKey: CJZRVARTODENJN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 56841944
TTD ID: D01SPJ

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 9 (TLR9)	TTSHG0T	TLR9_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Glioblastoma multiforme

ICD Disease Classification

2A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Toll-like receptor 9 (TLR9)	DTT	TLR9	2.58E-01	-0.06	-0.17

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of Oligovax SAS.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759).